Alabama Oncology considers clinical research to be an important part of our overall mission, and we are proud to provide access to clinical trials as a part of your care.

If you think you might be interested in taking part in a clinical trial and would like to speak to someone for more information, please ask your physician or contact a clinical research coordinator at (205) 263-9746.

Please see the current list of studies we have available for our patients below:

Treatment Studies:

Breast

Triple Negative Breast Cancer

• Gilead Ascent-05: Phase III Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)
  • https://clinicaltrials.gov/study/NCT05633654

ER Positive, HER2 Negative:

• BeOne BGB-43995-302: BGB-43395 Plus Letrozole Versus CDK4/​6i Plus Letrozole for Patients With Advanced or Metastatic HR+/​HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (KANDELA-302)
  • https://clinicaltrials.gov/study/NCT07492641
• PUMA AL1 1201: A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)
  • https://clinicaltrials.gov/study/NCT06369285

Lung

 Non-Small Cell Lung Cancer

• Revolution Medicine: RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
  • http://• https://clinicaltrials.gov/study/NCT06881784

• Pfizer C5851005: A Study to Learn About the Study Medicine Called PF-08046054/ SGN-PDL1V Versus Docetaxel in Adult Participants with Previously treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  • http://• https://clinicaltrials.gov/study/NCT07144280

• BioNTech BNT327-06: Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  • https://clinicaltrials.gov/study/NCT06712316

 Small Cell Lung Cancer

• AbbVie M23-384: A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/ Refractory Small Cell Lung Cancer
  • https://clinicaltrials.gov/study/NCT07365241

Ovarian

 Platinum Resistant Ovarian Cancer

• AstraZeneca Trevi-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01)
  • http://• https://clinicaltrials.gov/study/NCT07218809

Observational / Biomarker Studies:

Various Tumor types

• AstraZeneca PanTumor Destiny-04: Effectiveness of EnHertu Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study
  • https://clinicaltrials.gov/study/NCT07124000
• Exact Sciences ES2021-05: Multi cancer early detection (MCED) test development for newly diagnosed or recurrent cancers
  • https://www.exactsciences.com/Pipeline-and-Data/clinical-studies
• Flatiron Health PRWS: Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
  • https://clinicaltrials.gov/study/NCT06605404
• Natera ENCORE: Molecular Residual Disease (MRD) Detection and Monitoring in Solid Tumors and Hematologic Malignancies
  • https://www.natera.com
• MT7636: A biomarker study for Breast Cancer, Colorectal Cancer and Non-Small Cell Lung Cancer
  • https://mtgroupbio.com/
• Tempus ARIES: A biobank registry for various tumor types
  • https://clinicaltrials.gov/study/NCT06207032

Lung

• Tempus GEMINI NSCLC: A biobank registry for non-small cell lung cancer
  • https://clinicaltrials.gov/study/NCT05236114

Breast

• Tempus GEMINI Breast: A biobank registry for Breast Cancer
  • https://clinicaltrials.gov/study/NCT07211178